Does Hydrogen-Rich Water Reduce Oxidative Stress in Patients with Chronic Mountain Sickness? A Randomized, Blinded, Controlled Trial.
Fengying Zhang, Yang Zhong, Qiuyue Li, Doudou Hao, Zhiyou Shi, Suying Zhu, Qian Zhang, Yunhong Wu · High altitude medicine & biology · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In with untreated CMS (defined by Qinghai score) were randomly, adverse events occurred in 50% (15/30) of the hydrogen group and 37% (11/29) of the placebo group; dizziness was the most common. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in with untreated CMS (defined by Qinghai score) were randomly. Adverse events occurred in 50% (15/30) of the hydrogen group and 37% (11/29) of the placebo group; dizziness was the most common.
What the Researchers Studied
The researchers studied with untreated CMS (defined by Qinghai score) were randomly. The study used a randomized, placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen exposure: 990 mL hydrogen-rich water/day; dissolved H₂ concentration was not sufficiently reported, so H2HUBB did not estimate milligrams of H₂. Adverse events occurred in 50% (15/30) of the hydrogen group and 37% (11/29) of the placebo group; dizziness was the most common. The authors concluded that HRW demonstrated both pro-oxidative and antioxidative effects in CMS.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was with untreated CMS (defined by Qinghai score) were randomly. The study used a randomized, placebo-controlled human clinical trial. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen exposure was 990 mL hydrogen-rich water/day; dissolved H₂ concentration was not sufficiently reported, so H2HUBB did not estimate milligrams of H₂.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.